What are the recommended dosing and treatment strategies for using quetiapine (first‑line) versus mirtazapine (second‑line) in patients with hyperactive delirium that is most prominent at night?

Quetiapine vs Mirtazapine for Nighttime Hyperactive Delirium

Use quetiapine 25 mg orally at bedtime as first-line treatment for hyperactive delirium that is most prominent at night, not mirtazapine. Mirtazapine is not indicated for delirium treatment and should not be used for this purpose.

Rationale for Quetiapine

The 2018 ESMO guidelines explicitly list quetiapine as a pharmacological option for delirium symptom management, while mirtazapine is completely absent from delirium treatment recommendations 1. Quetiapine is specifically noted as "sedating" and "less likely to cause extrapyramidal side effects (EPSEs) than another atypical antipsychotic," making it particularly suitable for nighttime hyperactive delirium 1.

Quetiapine Dosing Strategy

Start with 25 mg immediate-release orally at bedtime 1. For persistent symptoms:

• Give every 12 hours if scheduled dosing is required
• Reduce dose in older patients and those with hepatic impairment
• Oral route only (no parenteral formulation available)
• Titrate to effect, with doses ranging from 25-800 mg daily being safe in ICU settings 2

Recent evidence shows quetiapine can be titrated quickly to higher doses (median 150 mg daily, maximum 225 mg) with minimal adverse effects 2. In refractory hyperactive delirium, quetiapine achieved delirium resolution within a median of 4 days when other agents failed 3. A 2024 RCT demonstrated quetiapine was equally effective as haloperidol for hyperactive delirium, with the added benefit of significantly reduced ICU length of stay (10.1 vs 11.7 days, p=0.018) and increased nighttime sleep hours 4.

Why Not Mirtazapine

Mirtazapine is an antidepressant, not an antipsychotic, and has no established role in delirium management. The FDA label indicates mirtazapine is approved only for major depressive disorder 5. Critical concerns include:

• May worsen delirium: The FDA label warns mirtazapine can cause agitation, confusion, and hallucinations—core features of hyperactive delirium 5
• No evidence base: A 2024 study adding mirtazapine to quetiapine in agitated Alzheimer's patients showed no benefit for agitation 6
• Contraindicated drug interactions: Mirtazapine has dangerous interactions with antipsychotics and can cause serotonin syndrome 5
• Sedation without antipsychotic effect: While sedating, it lacks the dopamine antagonism needed to treat delirium's perceptual disturbances

Clinical Implementation Algorithm

1. Confirm hyperactive delirium using CAM-ICU or similar validated tool
2. Address reversible causes first (medications, metabolic derangements, infection, pain)
3. Initiate quetiapine 25 mg PO at bedtime as PRN dosing initially 1
4. Assess response after 1-2 hours; may repeat if inadequate effect
5. Convert to scheduled dosing (25-50 mg q12h) if symptoms persist beyond 24-48 hours
6. Titrate upward by 25-50 mg increments every 1-3 days as needed, typically reaching 100-200 mg daily
7. Monitor for: orthostatic hypotension, excessive sedation, QTc prolongation (though risk is minimal 2)

Important Caveats

• Start PRN, not scheduled: Guidelines emphasize starting medications on an as-needed basis, converting to scheduled dosing only for persistent symptoms 1
• Use lowest effective dose for shortest duration: All antipsychotics carry risks and should be minimized 1
• No medication is licensed for delirium worldwide: This is off-label use based on clinical practice patterns 1
• Bedtime vs BID dosing: A 2024 study found no significant difference in delirium outcomes between once-daily bedtime dosing and twice-daily dosing, suggesting bedtime dosing may be reasonable to reduce daytime somnolence 7
• ICU guidelines are more restrictive: The 2018 Critical Care Medicine guidelines suggest NOT routinely using antipsychotics for delirium treatment in ICU patients, though this applies to broader ICU populations 8. The ESMO guidelines are more permissive for symptomatic management when patients have perceptual disturbances or severe agitation 1

The evidence strongly supports quetiapine over mirtazapine, as mirtazapine has no role in delirium management and may actually worsen symptoms.